Soluble guanylate cyclase activation with cinaciguat: A new approach to the treatment of decompensated heart failure

Cardiology in Review

Volumn 19, Issue 1, 2011, Pages 23-29

  Hingorany, Shipra ^a   Frishman, William H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

BAY 58 2667; cinaciguat; heart failure; sGC activator; soluble guanylate cyclase

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; CINACIGUAT; CYCLIC GMP; DIURETIC AGENT; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; LIFICIGUAT; NITRIC OXIDE;

CARDIOVASCULAR DISEASE; CREATININE BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEMODYNAMICS; HUMAN; HYPOTENSION; KIDNEY FUNCTION; MALE; MULTICENTER STUDY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SINGLE BLIND PROCEDURE; UNSPECIFIED SIDE EFFECT;

ANIMALS; BENZOIC ACIDS; CYCLIC GMP; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATORS; GUANYLATE CYCLASE; HEART FAILURE; HUMANS; NITRIC OXIDE; OXIDATIVE STRESS;

EID: 78650782368     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181fc1c10     Document Type: Review

References (49)

1. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics- 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69-e171.
2. Haldeman GA, Croft JB, Giles WH, et al. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995. Am Heart J.1999;137:352-360.
3. Hunt S; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure). J Am Coll Cardiol. 2005;46:e1-e82. (Pubitemid 41316530)
4. Gladwin MT. Deconstructing endothelial dysfunction: Soluble guanylyl cyclase oxidation and the NO resistance syndrome. J Clin Invest. 2006;116: 2330-2332.
5. Busse R, Fleming I. Vascular endothelium and blood flow. Handb Exp Pharmacol. 2006;176:43-78.
6. Hoenicka M, Schmid C. Cardiovascular effects of modulators of soluble guanylyl cyclase activity. Cardiovasc Hematol Agents Med Chem. 2008;6: 287-301.
7. Denninger JW, Marletta MA. Guanylate cyclase and the NO/cGMP signaling pathway. Biochim Biophys Acta. 1999;1411:334-350.
8. Ignarro LJ, Degnan JN, Baricos WH, et al. Activation of purified guanylate cyclase by nitric oxide requires heme. Comparison of heme-deficient, hemereconstituted and heme-containing forms of soluble enzyme from bovine lung. Biochim Biophys Acta. 1982;718:49-59.
9. Ignarro LJ, Adams JB, Horwitz PM, et al. Activation of soluble guanylate cyclase by NO-hemoproteins involves NO-heme exchange. Comparisons of heme-containing and heme-deficient enzyme forms. J Biol Chem. 1986;261:4997-5002.
10. Arnold WP, Mittal CK, Katsuki S, et al. Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci U S A. 1977;74:3203-3207.
11. Schmidt HH, Walter U. NO at work. Cell. 1994;78:919-925.
12. Lincoln TM. Cyclic GMP and mechanisms of vasodilation. Pharmacol Ther. 1989;41:479-502.
13. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83:1774-1777.
14. Mellion BT, Ignarro LJ, Ohlstein EH, et al. Evidence for the inhibitory role of guanosine 3', 5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood. 1981;57:946-955.
15. Boerrigter G, Burnett JC Jr. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. Cardiovasc Drug Rev. 2007;25:30-45.
16. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 1986; 320:454-456.
17. Valgimigli M, Merli E, Malagutti P, et al. Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress. Arch Biochem Biophys. 2003;420:255-261.
18. John S, Schmieder RE. Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia. Curr Hypertens Rep. 2003;5:199-207.
19. Melichar VO, Behr-Roussel D, Zabel U, et al. Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc Natl Acad Sci U S A. 2004;101:16671-16676.
20. Stasch JP, Schmidt PM, Nedvetsky PI, et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest. 2006;116:2552-2561.
21. Supaporn T, Sandberg SM, Borgeson DD, et al. Blunted cGMP response to agonists and enhanced glomerular cyclic 3'-5'-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int. 1996;50:1718-1725.
22. Weber M, Lauer N, Mülsch A, et al. The effect of peroxynitrite on the catalytic activity of soluble guanyly cyclase. Free Radic Biol Med. 2001;31:1360-1367.
23. Schrammel A, Behrends S, Schmidt K, et al. Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol. 1996;50:1-5.
24. Taylor AL, Ziesche S, Yancy CW, et al. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistence across subgroups in the African-American Heart Failure Trial. Circulation. 2007;115:1747-1753.
25. Msnzel T, Daiber A, Mülsch A, et al. Explaining the phenomenon of nitrate tolerance. Circ Res. 2005;97:618-628.
26. Warnholtz A, Mollnau H, Heitzer T, et al. Adverse effects of nitroglycerin treatment on endothelial function, vascular nitrotyrosine levels and cGMPdependent protein kinase activity in hyperlipidemic Watanbe rabbits. J Am Coll Cardiol. 2002;40:1356-1363.
27. Ko FN, Wu CC, Kuo SC, et al. YC-1, a novel activator of plately guanylate cyclase. Blood. 1994;84:4226-4233.
28. Wu CC, Ko FN, Kuo SC, et al. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol. 1995;116:1973-1978.
29. Mülsch A, Bauersachs J, Schäfer A, et al. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol. 1997;120:681-689.
30. Galle J, Zabel U, Hübner U, et al. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol. 1999;127:195-203.
31. Boerrigter G, Burnett JC Jr. Soluble guanylate cyclase. Not a dull enzyme. Circulation. 2009;119:2752-2754.
32. Stasch JP, Becker EM, Alonso-Alija C, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature. 2001;410:212-215. (Pubitemid 32216593)
33. Mullershausen F, Russwurm M, Friebe A, et al. Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272. Circulation. 2004;102:1711-1713.
34. Zanfolin M, Faro R, Araujo EG, et al. Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats. J Cardiovasc Pharmacol. 2006;47:391-395.
35. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, et al. Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation. 2003;107:686-689.
36. Ahluwalia A, Foster P, Scotland RS, et al. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. Proc Natl Acad Sci U S A. 2004;101:1386-1391.
37. Stasch JP, Schmidt P, Alonso-Alija C, et al. NO- and heme-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol. 2002;136:773-783.
38. Friebe A, Schultz G, Koesling D. Sensitizing soluble guanylate cyclase to become a highly CO-sensitive enzyme. EMBO J. 1996;15:6863-6868.
39. Hoenicka M, Becker EM, Apeler H, et al. Purified soluble guanylyl cyclase expressed in a baculovirus Sf9 system: stimulation of YC-1, nitric oxide, and carbon monoxide. J Mol Med. 1999;77:14-23.
40. Garthwaite J, Southam E, Boulton CL, et al. Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo [4,3-a]quinoxalin-1-one. Mol Pharmacol. 1995;48:184-188.
41. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, et al. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension. 2007;49:1128-1133.
42. Frey R, Mück W, Unger S, et al. Pharmacokinetics, pharmacodynamics,tolerability, and safety of the soluble guanylate cyclase activator Cinaciguat(BAY 58-2667) in healthy male volunteers. J Clin Pharmacol. 2008;48:1400-1410.
43. Lapp H, Mitrovic V, Franz N, et al. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation. 2009;119:2781-2788.
44. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
45. Korkmaz S, Radovits T, Barnucz E, et al. Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury. Circulation. 2009;120:677-686.
46. Krieg T, Liu Y, Rütz T, et al. BAY 58-2667, a nitric oxide-independent guanylyl cylcase activator, pharmacoligcally post-conditions rabbit and rat hearts. Eur Heart J. 2009;30:1607-1613.
47. Dumitrascu R, Weissmann N, Ghofrani HA, et al. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation. 2006;113:286-295.
48. Chester M, Tourneux P, Seedorf G, et al. Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus. Am J Physiol Lung Cell Mol Physiol. 2009;297:318-325.
49. Kalk P, Godes M, Relle K, et al. NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy.Br J Pharmacol. 2006;148:853-859.